Seminars in Oncology

• 

  Publication Venue For

  • Advances in inherited cancers: Introduction..  43:527. 2016
  • Adjuvant Chemotherapy for Stage II Rectal Cancer..  42:e99-107. 2015
  • Synchronous primary carcinoma of breast and ovary versus ovarian metastases..  42:e13-e24. 2015
  • Premalignant cystic neoplasms of the pancreas..  42:70-85. 2015
  • The role of surgery and ablative radiotherapy in oligometastatic breast cancer..  41:790-797. 2014
  • Antibody-based immunotherapy for malignant glioma..  41:496-510. 2014
  • Energy balance and metabolism after cancer treatment..  40:745-756. 2013
  • Introduction: The science of survivorship: moving from risk to risk reduction..  40:662-665. 2013
  • Solid tumor second primary neoplasms: who is at risk, what can we do?.  40:676-689. 2013
  • Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy..  39:305-310. 2012
  • Low-grade follicular lymphoma of the small intestine: a challenge for management..  38:714-720. 2011
  • Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?.  38 Suppl 3:S30-S42. 2011
  • International perspective: outcomes of palliative oncology..  38:343-350. 2011
  • Personalized treatment of lung cancer..  38:274-283. 2011
  • The importance of identifying and validating prognostic factors in oncology..  37:e9-18. 2010
  • Fatigue in older cancer patients: etiology, assessment, and treatment..  35:633-642. 2008
  • Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B..  35:470-483. 2008
  • Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer..  35:251-261. 2008
  • Salivary gland malignancies: the role for chemotherapy and molecular targeted agents..  35:309-319. 2008
  • Screening and prevention of hereditary gynecologic cancers..  34:406-410. 2007
  • Surgical therapy of cutaneous melanoma..  34:270-280. 2007
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events..  33:S26-S34. 2006
  • Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice..  33:S35-S40. 2006
  • Myelotoxicity from chemotherapy..  33:74-85. 2006
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer..  32:S35-S41. 2005
  • Combined modality treatment for rectal cancer..  32:103-112. 2005
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer..  32:61-68. 2005
  • Descriptive epidemiology and risk factors for head and neck cancer..  31:726-733. 2004
  • The importance of chemotherapy dose intensity in lung cancer..  31:25-31. 2004
  • Breast cancer in older patients..  31:234-248. 2004
  • Geriatric assessment and comorbidity..  31:149-159. 2004
  • Molecular classification and molecular genetics of human lung cancers.  31:4-19. 2004
  • Molecular classification and molecular genetics of human lung cancers..  31:4-19. 2004
  • Molecular Classification and Molecular Genetics of Human Lung Cancers.  31:4-19. 2004
  • Nutrition-related issues for the breast cancer survivor..  30:789-798. 2003
  • Balancing the benefits and costs of colony-stimulating factors: a current perspective..  30:10-17. 2003
  • Combined modality therapy for rectal and colon cancer..  30:101-112. 2003
  • Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia..  30:24-30. 2003
  • Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer..  30:39-50. 2003
  • Quantitating cellular immune responses to cancer vaccines.  30:9-16. 2003
  • Quantitating cellular immune responses to cancer vaccines..  30:9-16. 2003
  • Cost-effectiveness considerations in the treatment of essential thrombocythemia..  29:28-32. 2002
  • The role of imaging in malignant pleural mesothelioma..  29:26-35. 2002
  • Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality.  29:2-8. 2002
  • Platelet-derived growth factor receptors: a therapeutic target in solid tumors..  28:27-33. 2001
  • Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report..  28:40-44. 2001
  • Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate..  28:8-15. 2001
  • Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index..  28:25-33. 2001
  • Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report.  28:40-44. 2001
  • Platelet-derived growth factor receptors: A therapeutic target in solid tumors.  28:27-33. 2001
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.  27:35-40. 2000
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.  27:S35-S40. 2000
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis..  27:35-40. 2000
  • A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.  26:39-44. 1999
  • A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.  26:39-44. 1999
  • A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780..  26:39-44. 1999
  • Imaging lung cancer.  26:21-26. 1999
  • Imaging lung cancer..  26:21-26. 1999
  • Imaging lung cancer.  26:21-26. 1999
  • Hematopoietic growth factors in the reduction of chemotherapeutic toxicity..  25:552-561. 1998
  • Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma..  25:447-460. 1998
  • Exercise and the treatment of wasting: aging and human immunodeficiency virus infection..  25:112-122. 1998
  • Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia..  25:80-97. 1998
  • Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results..  24:S19-57-S19-61. 1997
  • Hyperthermic treatment of malignant diseases: current status and a view toward the future..  24:616-625. 1997
  • Intraoperative irradiation: current and future status..  24:715-731. 1997
  • A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.  24. 1997
  • A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer..  24:S12-130-S12-134. 1997
  • Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.  24. 1997
  • Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer..  24:S8-42-S8-45. 1997
  • Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience..  23:43-48. 1996
  • Phase I studies with the novel nucleoside analog gemcitabine..  23:25-31. 1996
  • Epirubicin and ifosfamide in metastatic breast cancer.  23:28-33. 1996
  • Epirubicin and ifosfamide in metastatic breast cancer..  23:28-33. 1996
  • Update on the role of vinorelbine in the treatment of non-small cell lung cancer: Introduction.  23:1. 1996
  • Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1)..  23:22-24. 1996
  • Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2)..  23:53-55. 1996
  • Update: vinorelbine (navelbine) in non-small cell lung cancer..  23:2-7. 1996
  • High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer..  23:60-67. 1996
  • Phase I studies with the novel nucleoside analog gemcitabine.  23:25-31. 1996
  • A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: A study of the North Central Cancer Treatment Group.  22:75-77. 1995
  • A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group..  22:75-77. 1995
  • The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy..  22:18-22. 1995
  • Geriatric principles of treatment applied to medical oncology: an overview..  22:1-2. 1995
  • Geriatric principles of treatment applied to medical oncology: An overview.  22:1-2. 1995
  • The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer.  21:25-31. 1994
  • Vinorelbine (Navelbine) in non-small cell lung cancer: future directions..  21:85-88. 1994
  • Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor..  21:73-78. 1994
  • Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience..  21:60-65. 1994
  • Immunobiology of malignant astrocytomas..  21:149-161. 1994
  • Nonoperative management of non-small cell lung cancer: The current Cancer and Leukemia Group B experience.  21:60-65. 1994
  • The biology of unknown primary tumors..  20:238-243. 1993
  • Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy..  19:33-37. 1992
  • alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action..  18:71-76. 1991
  • Chemotherapy-induced emergencies..  16:572-578. 1989
  • Identification and assessment of prognostic factors..  15:462-471. 1988
  • Immunobiology of human gliomas..  13:94-109. 1986
  • Mitoxantrone in the treatment of relapsed and refractory acute leukemia.  11:41-46. 1984
  • Advances in the treatment of tumors arising in bone..  1:47-55. 1974
  • Evolving concepts in chemotherapy and surgery for bilio-pancreatic cancer: Introduction 2002
  • Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. 2002
  • Epidermal growth factor receptor-targeted therapy for pancreatic cancer. 2002
  • Use of amifostine in bone marrow purging. 1996